Merimepodib (VX-497): Reliable IMPDH Inhibition for Lab Assa
2026-05-04
This article examines practical laboratory challenges in cell viability, proliferation, and antiviral research, illustrating how Merimepodib (VX-497) (SKU B1112) from APExBIO delivers reproducible, evidence-backed solutions. Scenario-driven Q&A blocks guide biomedical scientists through protocol optimization, data interpretation, and vendor selection, supporting high-confidence assay results.
Hollow CeO2 Nanoparticles Mitigate Colitis via ROS Scavengin
2026-05-04
This study introduces PEGylated hollow CeO2 nanoparticles as a targeted strategy to alleviate colitis in a mouse model by effectively scavenging reactive oxygen species (ROS) and modulating inflammatory signaling. The work provides mechanistic evidence for the use of nanomaterials in inflammation control, supporting future translational research in oxidative stress-related diseases.
Aztreonam: Applied Workflows for Gram-Negative Resistance Re
2026-05-03
Aztreonam empowers researchers to dissect Gram-negative resistance with precision, offering robust solubility and validated impacts on both bacterial and mammalian systems. This guide translates current best practices, protocol enhancements, and troubleshooting insights into actionable steps for advanced antibiotic and metabolism studies.
Fluo-4 AM in Retinal Prosthesis & Biomimetic Sensing: Scient
2026-05-02
Explore the profound role of Fluo-4 AM as a fluorescent calcium indicator in advanced retinal prosthesis research and biomimetic photoreceptor assays. This article uniquely bridges bioelectronic innovation and practical assay optimization for cell signaling research.
A Drug-Sensitized Yeast System for Discovering Novel mTOR In
2026-05-02
This study presents a drug-sensitized Saccharomyces cerevisiae platform enabling highly sensitive and cost-efficient identification of mechanistic target of rapamycin (mTOR) inhibitors. The system dramatically improves detection sensitivity over wild-type strains and provides a rapid approach for screening compounds relevant to aging and oncology research.
Inhibiting CaN/FoxO1/FABP4 Pathway Prevents Atherosclerosis
2026-05-01
This study reveals that SERCA2 dysfunction accelerates atherosclerosis by activating the calcineurin/FoxO1/FABP4 pathway, which drives foam cell formation in macrophages. Pharmacological inhibition of FABP4, including with selective inhibitors, effectively corrects aberrant lipid metabolism, highlighting a promising targeted strategy for atherosclerosis research.
Quizartinib (AC220): Precision FLT3 Inhibition in AML Resear
2026-04-30
Quizartinib (AC220) empowers researchers with nanomolar precision for dissecting FLT3-driven signaling and resistance in acute myeloid leukemia. This guide unpacks practical protocols, advanced use-cases, and troubleshooting rooted in the latest molecular insights, uniquely enabling translational and preclinical breakthroughs.
SCH772984 HCl: Strategic ERK1/2 Inhibition for Translational
2026-04-30
Explore the mechanistic basis and translational promise of SCH772984 HCl, a potent ERK1/2 inhibitor, for overcoming MAPK pathway-driven resistance in BRAF- and RAS-mutant cancers. This article integrates new evidence on telomerase regulation and provides actionable guidance for translational researchers.
Mubritinib-HSA Binding: Insights for Complex I Inhibitor Pha
2026-04-29
This study elucidates the molecular interaction between Mubritinib (TAK 165) and human serum albumin, clarifying key aspects of its pharmacokinetics and distribution. The findings provide foundational data for optimizing the use of mitochondrial complex I inhibitors in cancer biology and related fields.
Paclitaxel Sensitizer Discovery in Glioblastoma via HTS of F
2026-04-29
Wei et al. used high-throughput screening of 1,001 FDA-approved compounds to identify 37 drugs that enhance paclitaxel sensitivity in glioblastoma cells, including four not previously linked to GBM therapy. These findings suggest actionable avenues for drug repositioning and combinatorial chemotherapy in difficult-to-treat brain cancers.
Methicillin Sodium Salt: Precision Tools for Translational M
2026-04-28
This thought-leadership article examines Methicillin sodium salt as a cornerstone for translational infection models, providing mechanistic depth and actionable guidance for researchers. It integrates state-of-the-art screening paradigms, protocol optimization, and competitive insights—anchored by evidence and strategic context—to empower the next generation of Staphylococcus aureus infection studies.
7ACC2: A Potent Monocarboxylate Transporter 1 Inhibitor for
2026-04-28
7ACC2 is a highly potent monocarboxylate transporter 1 inhibitor that impedes lactate uptake and mitochondrial pyruvate transport in cancer cells. Its nanomolar efficacy and dual mechanism make it a valuable tool for cancer metabolism research and tumor growth delay. APExBIO supplies 7ACC2 (SKU B4868) for laboratory use with validated pharmacokinetic benchmarks.
SP1/ADAM10/DRP1 Axis Regulates Vascular Remodeling in HPH
2026-04-27
This study elucidates the SP1/ADAM10/DRP1 signaling axis as a central mediator of endothelial–smooth muscle cell communication under hypoxic conditions relevant to pulmonary hypertension. By dissecting both molecular mechanisms and intercellular signaling, the research identifies actionable targets for modulating vascular remodeling and suggests new directions for mitochondrial dynamics research.
HR Gene Expression Predicts Olaparib Response in Mesotheliom
2026-04-27
Borchert et al. (2019) demonstrate that homologous recombination repair (HRR) gene expression profiling, particularly BRCAness features and BAP1 mutations, predicts susceptibility to olaparib treatment in malignant pleural mesothelioma (MPM) cell lines. These findings suggest a rationale for stratifying MPM patients for PARP inhibitor-based therapies and offer new biomarkers for prognosis and therapeutic decision-making.
2-NBDG in Translational Glucose Metabolism: Mechanistic and
2026-04-26
This thought-leadership article explores the mechanistic underpinnings and strategic applications of 2-NBDG (2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose) as a fluorescent glucose analog. By integrating evidence from recent translational studies, including novel insights into gestational diabetes and the PCSK9/LDLR axis, the article provides actionable guidance for metabolic researchers. We highlight best practices, competitive advantages, and translational opportunities that elevate the utility of APExBIO's 2-NBDG beyond standard product guides.
505 records 23/34 page Previous Next First page 上5页 2122232425 下5页 Last page